Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy

By F. Chang, John T. Lee, P. Navolanic, Linda S. Steelman, J. G. Shelton, W. Blalock, R. Franklin, J. McCubrey. Leukemia, 2003

1,232 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. (2007, background): “Among these targets are: Bad, Bim, procaspase-9, IκKalpha, the forkhead family of transcription factors (FKHR/AFX now called FOXO3a), GSK-3β, MDM-2, p21, p27 and others [91,111,112].”
Molecular targets of dietary agents for prevention and therapy of cancer. (2006, background): “[88] Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, et al.”
A Logical Model Provides Insights into T Cell Receptor Signaling (2007, background): “Interestingly, components occurring in the MISs with few elements (Table 3) are in fact known oncogenes: ZAP70 [43], PI3K [44], Gab2 [45], and PLC c 1 [46] (and SLP76 is directly involved in PLC c 1 activation).”
PI3K/Akt and apoptosis: size matters (2003, background): “Recent studies that have identified endogenous inhibitors of PI3K/Akt signal transduction have significantly fueled and accelerated the effort to identify and characterize synthetic small-molecule compounds (Kim et al., 2002b; West et al., 2002; Chang et al., 2003).”